



7TH ANNUAL MEETING
Vilnius • 2023

7th Meeting of the European Hereditary Tumour Group (EHTG)

Friday, Sept 29th – Sunday, Oct 1st 2023

Vilnius, Lithuania

Preliminary Program



Invitation

7th Meeting - Vilnius, Lithuania

Dear Members, Friends, Affiliates and Sponsors,

We are delighted to invite you to the 7th annual EHTG meeting in beautiful Vilnius, Sept. 29 to Oct. 1 2023. Our lively program includes selected hot and controversial topics, debates, new interactive formats and our workshop day with in-depth scientific discussions. Join us in person or online during the hybrid event!

Days 1 (Friday) and 3 (Sunday) will follow the plenary format without parallel sessions. Day 2 (Saturday) is our dedicated working group (WG) day, with three parallel groups. The highest-rated abstracts will be allocated throughout the day for both days and into the working groups.

Additionally, our meeting dates are back-to-back with the European Society of Coloproctology's annual conference on Sept 27-29; we envisage bilateral synergistic effects to come from this. On Thursday, Sept. 28, we will host the ESCP-EHTG joint symposium at the ESCP venue. On Saturday, an additional EHTG-ESCP workshop is scheduled for clinicians interested in surgical management of hereditary predisposition syndromes.

After last year's successful launch, our 7th meeting provides an open platform for patient societies and networking. Continuing our international collaboration in this field, we welcome and encourage patients and patient societies to join us in person or virtually in Vilnius.

Vacation in beautiful Vilnius? Why not spend a few days before or after the meeting? Our venue, The Panorama Hotel, is located in Vilnius' old town, only 1.5km from the Gate of

Dawn. The hotel's top-floor lounge gives guests spectacular panoramic city views. The historic Gediminas Tower and Town Hall Square can be reached within a 15-minute walk. Or head out further afield with the bus and train stations only a 3-minute walk from the Hotel.

Visit www.ehtg.org for more information and contact gs007@ehtg.org for all organisational queries. If you have any suggestions, please get in touch with any of the board members.

We are genuinely excited to see you in Vilnius!

Sincerely, your EHTG Board Members





Content

Invitation	2-3
Organisation	5
Overview day 1	6
Overview day 2	7
Overview day 3	8
Day 1 – Friday, September 29th	
(wh)y-EHTG Session	10
Plenary Session 1	10
Big Debate	11
Panel discussion	11
Best of Abstracts	12
Welcome Reception	12
EHTG Nurses Meeting	13
y-EHTG Social Networking	12/13
Day 2 – Saturday, September 30th	
Open PLSD Meeting	14
Working Group 1	14-15
Working Group 2	15-17
Working Group 3	17-18
Working Group 4	18-19
Working Group 6	19-20
Working Group 7	20-21
Working Group 8	22
Working Group 9	23
CMMRD Session	24-25
EHTG-ESCP international Surgery Day	26-27
Conference Dinner	25
Day 3 – Sunday, October 1st	
EHTG Business Meeting	28
WG Reporting Back Session and Collaborative Studies ..	28
Hot Topic / Late Breaking Abstracts	28
Session Pathology and clinical data in childhood	28
Newly emerging technologies	29
Farewell	29

Organisation

Board Members: Aysel Ahadova (Germany)
 Peter Bauerfeind (Switzerland)
 John Burn (United Kingdom)
 Mev Dominguez Valentin (Norway)
 Fiona Laloo (United Kingdom)
 Gabriela Moslein (Germany)
 Pål Møller (Norway)
 Julian Sampson (United Kingdom)
 Toni Seppala (Finland)
 Rolf Sijmons (Netherlands)
 Sanne ten Broeke (Netherlands)

Program Committee: Mev Dominguez Valentin (Norway)
 Aysel Ahadova (Germany)
 Elizabeth Half (Israel)
 Kelly Kohut (UK)
 Neil Ryan (UK)
 Sanne ten Broeke (Netherlands)
 Laura Thomas (UK)
 Ingrid Winship (Australia)

Secretariat: Gabriele Sponholz
gs007@ehtg.org
 +49-160-8459502
 D-65207 Wiesbaden (Germany)

Location: Panorama Hotel, Vilnius, Lithuania
<https://panoramahotel.lt/reservation@panoramahotel.lt>
 Only direct booking

Registration: Only online via www.ehtg.org

Registration Fee: See online via www.ehtg.org

Certification: We have applied for certification by EACCME and expect the same certification as last year (6/8/5)

Meeting Overview

Day 1 – Friday, September 29th

Time	Event
08:00 - 09:00	Registration
09:00 - 11:00	(wh)y-EHTG Session
11:00 - 11:30	Coffee Break
11:30 - 13:30	Plenary Session 1 (6 talks)
13:30 - 14:30	Industry Symposium / Lunch
14:30 - 15:15	Big Debate
15:15 - 16:15	Panel discussion Gynaecological Surveillance
16:15 - 16:45	Coffee Break
16:45 - 17:45	Best of Abstracts (n=12)
17:45 - 18:15	Welcome Reception
17:45 - 18:15	EHTG Nurses Meeting
20:00 +	y-EHTG Social Networking

We look forward to your personal attendance, but also offer the meeting with all sessions live online.

Meeting Overview

Day 2 – Saturday, September 30th

Time	Event
08:00 - 09:00	Open PLSD Meeting
09:00 - 11:00	Parallel Working Groups 1 - 3 EHTG-ESCP international Surgery Day "iSTOIC"
11:00 - 11:30	Coffee Break
11:30 - 13:30	Parallel Working Groups 4 + 6 EHTG-ESCP international Surgery Day "iSTOIC"
13:30 - 14:30	Lunch
14:30 - 16:30	Parallel Working Groups 7 - 9 EHTG-ESCP international Surgery Day "iSTOIC"
	* International Surgical Group of Those Operating on Inherited colorectal Cancer
16:30 - 17:00	Coffee Break
17:00 - 18:30	CMMRD Session
19:30 +	Conference Dinner

We look forward to your personal attendance, but also offer the meeting with all sessions live online.



Scientific Program

Day 1 – Friday, September 29th

08:00-09:00 Registration

09:00-11:00 **(wh)y-EHTG Session**
Chairs: Sanne Bajwa-ten Broeke (Netherlands)
Demetra Georgiou (UK)
Aysel Ahadova (Germany)

09:00-09:10 1. Top abstract

09:10-09:20 2. Top abstract

09:20-09:30 3. Top abstract

09:30-10:00 Y-EHTG Dragons Den for new proposals

10:00-11:00 Y-EHTG show & tell

11:00-11:30 Coffee Break

11:30-13:30 **Opening remarks**
Gabriela Moeslein (Germany)

Plenary Session 1

Chairs: Ann-Sofie Backman (Sweden)
Ingrid Winship (Australia)
Zohar Levi (Israel)

11:30-11:50 **Clinical Translation of Cancer Immunoprevention**
Shizuko Sei (USA)

11:50-12:10 **Evolving therapy of MMR deficient CRC**
Frank A. Sinicrope (USA)

12:10-12:30 **TBD**
 NN

12:30-12:50 **New updated guidelines for FAP**
Gloria Zaffaroni (Italy)

Scientific Program

Day 1 – Friday, September 29th

12:50-13:10 **Prenatal and Preimplantation Genetic Diagnosis**
Yael Goldberg (Israel)

13:10-13:30 **Guidelines for transgender care in Lynch Syndrome / Transgender challenges in healthcare**
Rachel Hodan (USA)
Esther van Enckevort (Netherlands)

13:30-14:30 Industry Symposium/Lunch

14:30-15:15 **Big Debate – Urological Surveillance**
Chairs: Elizabeth Half (Israel)
Richard Gallon (UK)

Urological surveillance in Lynch Syndrome is necessary / not necessary?
Marco Moschini (Italy)
Ulla Nordstroem (Denmark)

15:15-16:15 **Panel discussion Gynaecological Surveillance**
Is there a role for gynaecological surveillance in Lynch syndrome/HBOCS?
Chairs: Neil Ryan (UK)
Emma Crosbie (UK)
Anja Wagner (Netherlands)

15:15-15:25 **Ovarian cancer prevention in high-risk groups**
Robert Fruscio (Italy)

15:25-15:35 **Universal germline testing and/or dMMR tumor screening among all endometrial cancer patients**
Heather Hampel (USA)

15:35-15:45 **Gynaecological surveillance in high-risk groups in The Netherlands**
Ellis Eikenboom (Netherlands)

15:45-16:15 Panel Discussion

16:15-16:45 Coffee Break

Scientific Program

Day 1 – Friday, September 29th

16:45-17:45

Best of Abstracts

Chairs: Gabriel Capella (Spain)

TBD

TBD

1) Best of Abstracts
NN

2) Best of Abstracts
NN

3) Best of Abstracts
NN

4) Best of Abstracts
NN

5) Best of Abstracts
NN

6) Best of Abstracts
NN

7) Best of Abstracts
NN

8) Best of Abstracts
NN

9) Best of Abstracts
NN

10) Best of Abstracts
NN

11) Best of Abstracts
NN

12) Best of Abstracts
NN

17:45-18:15

Welcome Reception

20:00 +

y-EHTG Social Networking

Scientific Program

Day 1 – Friday, September 29th

18:30-20:00

EHTG Nurses Meeting

18:30-18:35

Welcome and introduction

Laura Monje-Garcia (UK)

Mechelle Loughrey (Ireland)

18:35-18:45

Summary of role and objectives of the EHTG

Committee Member

18:45-19:15

Snapshot of current hereditary cancer nursing services

Mechelle Loughrey (Ireland)

Laura Monje-Garcia (UK)

Celia Diez de los Tios (Spain)

19:15-19:25

Opportunity for attendees to discuss their service

OPEN

19:25-19:35

Question time

OPEN

19:35-19:45

Service improvement +/- site visits, Research collaboration opportunities

Laura Monje-Garcia (UK)

Mechelle Loughrey (Ireland)

19:45-20:00

Brainstorming session re future meetings/ board membership etc.

OPEN

20:00 +

y-EHTG Social Networking



Scientific Program

Day 2 – Saturday, September 30th

08:00-09:00 Open PLSD Meeting

09:00-11:00 Joint ESCP-EHTG Hereditary Surgery Symposium
See page 24-25 for details

09:00-11:00 Parallel Working Groups 1-3

09:00-11:00 **Group 1 – Gastroenterology, Surveillance and Microbiom**

Chairs: Elizabeth Half (Israel)
Peter Bauerfeind (Switzerland)
Martina Cavestro (Italy)

15' + 5' **The role of genotoxic gut bacteria in hereditary and sporadic colorectal cancer**
Dan Buchanan (Australia)

Perceptions and Attitudes towards Faecal Immunochemical Testing (FIT) as a Provisional Modality for Risk-Stratified Colonoscopy in a Lynch Syndrome Patient Population
Kevin Monahan (UK)

The optimal endoscopic surveillance in hereditary diffuse type gastric cancer; random or targeted biopsy taking?
Tanya Bisseling (Netherlands)

The diagnostic yield of colonoscopic surveillance following resection of early-age onset colorectal cancer (EOCRC).
Husam Al Maliki (UK)

Four decades of endoscopic surveillance in Lynch syndrome reveals a slightly higher complication rate - a retrospective cohort study on safety and adverse events
Alexander Frank (Sweden)

Efficacy and Outcomes of Pancreatic Cancer Screening Program in CAPS-Eligible versus non-CAPS-Eligible populations: A Single Center Study
Erez Hasnis (Israel)

Scientific Program

Day 2 – Saturday, September 30th

Duodenal disease phenotype in MUTYH-associated polyposis: updated findings from an international prospective study.
Laura Thomas (UK)

The impact of a novel expert multidisciplinary meeting for the management of hereditary colorectal cancer risk
Avani Varde (UK)

Quality of Endoscopic Surveillance in Lynch Syndrome Patients at a Highly Specialized Center in Sweden - Interval, Adenoma Detection, and Cleanliness
Sophie Walton Bernstedt (Sweden)

Distinct gastric phenotype in patients with SMAD4-associated Juvenile Polyposis Syndrome: A nationwide study
Anne Marie Jelsing (Denmark)

Risk Factors and Clinical Characteristics of Young-Onset Gastric Cancer vs. Late-Onset Gastric Cancer: a case-case-study
Marta Puzzono (Italy)

Colibactin mutational signatures in NTHL1 Tumor Syndrome, MUTYH Associated Polyposis and unexplained polyposis patients
Diantha Terlouw (Netherlands)

Characterizing unique microbiome alterations in lynch syndrome within the druze community in Israel
Elizabeth Half (Israel)

09:00-11:00 **Group 2 – Carcinogenic mechanisms and pathways / early onset cancers / novel associations**
Chairs: Richarda de Voer (Netherlands)
Matthias Kloor (Germany)
Laura Thomas (UK)

5' + 2' **Arsenic-free diet can decrease the risk of cancers in females from families with aggregation of breast cancers**
Jan Lubinski (Poland)

Scientific Program

Day 2 – Saturday, September 30th

5' + 2' Additive effects of selenium and arsenic can be considered for effective diagnosis of significantly lower cancer risk in *brca1* carriers on arsenic free diet

Jan Lubinski (Poland)

5' + 2' Mathematical guidance for the interpretation of PCR-based MSI diagnostics

Alexander Zeilmann (Germany)

5' + 2' Mathematical modeling of Lynch syndrome cancer development - A multi-scale view from the DNA over the tissue level to clinical translation

Saskia Haupt (Germany)

8' + 2' Co-evolution of mismatch repair loss and the immune response in Lynch Syndrome

Ottilie Swinyard (UK)

8' + 2' The associations of circulating microRNAs and lifestyle with cancer risk among Finnish Lynch syndrome carriers

Tero Sievänen (Finland)

8' + 2' Leveraging whole exome sequencing of Lynch syndrome associated primary colorectal cancer to illuminate the aetiology of β -catenin dependent subtype.

Kalle Hokkanen (Finland)

8' + 2' Impact of Pathogenetic MMR Genotypes on Systemic Metabolomic Signatures

Tiina Jokela (Finland)

8' + 2' Genome-wide DNA methylation profiles of colorectal tumors in Lynch syndrome and Familial adenomatous polyposis

Satu Makinevala (Finland)

8' + 2' Germline NPAT pathogenic variants in hereditary nonpolyposis colorectal cancer

Mariona Terradas (Spain)

8' + 2' MCM8 and MCM9 as germline predisposing genes for early-onset cancer, polyposis and primary ovarian insufficiency

Noah Cornelis Helderma (Netherlands)

Scientific Program

Day 2 – Saturday, September 30th

8' + 2' Germline variants in PARP1 as potential cause of colonic polyposis in adults
Laura Valle (Spain)

09:00-11:00 **Group 3 – Families with inherited cancer/ organizations**

*Chairs: Nicola Reents (Germany)
Simone Widhalm (Germany)
Kelly Kohut (UK)*

8' + 3' Guidelines in „plain language“ for patients affected by Lynch syndrome

Katlijn Sanctorum (Belgium)

8' + 3' Co-design of patient information leaflets for cancer genetics

Julie Young (UK)

8' + 3' Co-design of the Lynch Choices patient resource including cultural translation to improve equity, diversity and inclusion

Kelly Kohut (UK)

8' + 3' The National Nursing Workshops: Adapting Delivery and Content to Increase Awareness of Lynch Syndrome.

Amy Sanderson (UK)

8' + 3' Diagnosis and management of Lynch Syndrome in an Irish Context: An Advanced Nurse Practitioner (ANP) Led Service

Mechelle Loughrey (Ireland)

8' + 3' The United Kingdom National NHS Genomic Lynch Syndrome Transformation Project: The Rise of the Genomic Practitioner

Mandy Darbyshire (UK)

8' + 3' The NHS English National Lynch syndrome transformation project: Setting up the Regional Lynch syndrome Expert Network for the North Thames Genomic Medicine Service Alliance (GMSA)

Anna Koziel (UK)

Scientific Program

Day 2 – Saturday, September 30th

8' + 3' A questionnaire-based assessment of holistic clinical care for Lynch syndrome linked to regular colonoscopic surveillance episodes
Penelope Edwards (UK)

8' + 3' Identifying barriers to colonoscopic screening in asymptomatic first-degree relatives of patients with hereditary CRC in Pakistan – A pilot study.
Raza Sayyed (Pakistan)

8' + 3' Finding the missing 95%: The English National Lynch syndrome transformation project
Kevin Monahan (UK)

11:00-11:30 **Coffee Break**

11:30-13:30 **Joint ESCP-EHTG Hereditary Surgery Symposium**
See page 24-25 for details

11:30-13:30 **Parallel Working Groups 4 + 6**

11:30-13:30 **Group 4 – Epidemiology of hereditary cancer**
Chairs: Sigurdís Haraldsdóttir (Iceland)
Heather Hampel (USA)
Mev Dominguez (Norway)

15' + 5' Integrated Germline-Somatic Analysis: Research Insights from the MSK-IMPACT Initiative
Zsofia Stadler (USA)

7' + 3' The rate of ATM pathogenic variants (PVs) in a series of unselected Israeli Pancreatic Cancer Patients
Rakefet Chen-Shtoyerman (Israel)

7' + 3' Colorectal cancer incidences in carriers with and without colorectal adenomas
Pål Møller (Norway)

7' + 3' Colorectal cancer incidences in path_MLH1 and path_MSH2 carriers in three continents
Pål Møller (Norway)

Scientific Program

Day 2 – Saturday, September 30th

7' + 3' Cancer in patients with Familial adenomatous polyposis - a nationwide Danish cohort study with matched controls
Anne Marie Jelsig (Denmark)

7' + 3' Whole genome sequencing findings in families tested negative based on family history
Mev Dominguez Valentin (Norway)

7' + 3' Incidence of adenomatous polyps and colorectal cancer in Dutch patients with PMS2-associated Lynch syndrome undergoing surveillance: a prospective cohort analysis
Katarina Andini (Netherlands)

7' + 3' Prevalence of familial pancreatic cancer and inherited cancer syndromes in pancreatic cancer patients in Iceland 2000-2021
Ásthildur Rafnsdóttir (Iceland)

11:30-13:15 **Group 6 – Personalized medicine targeted and prevention**
Chairs: Anja Wagner (Netherlands)
Nadir Arber (Israel)
Frank A. Sinicrope (USA)

20' + 10' Beyond Checkpoint Blockade for dMMR/MSI-High Cancers - Advances and Challenges
Kai-Keen Shiu (UK)

10' + 5' A significant proportion of advanced colonic neoplasia could have been missed, if we had adopted the recommendation to raise the age to start colonoscopy to 35 for subjects with path_MSH6 mutation
Zohar Levi (Israel)

10' + 5' Detection of microsatellite instability using plasma-derived extracellular vesicle DNA – a new perspective for tumor surveillance in Lynch syndrome?
Lena Bohaumilitzky (Germany)

10' + 5' Comprehensive molecular profiling of patient-derived tumor organoids uncovers in vitro drug sensitivities of sporadic and hereditary colorectal cancers
Erdogan Pekcan Erkan (Finland)

Scientific Program

Day 2 – Saturday, September 30th

10' + 5'	<p>Clinical Use Scenarios of Breast Cancer Polygenic Risk Score in Women <i>Peeter Padrik (Estonia)</i></p>
10' + 5'	<p>Nous-209 genetic vaccine encoding shared cancer neoantigens has demonstrated safety and robust immunogenicity in patients with Microsatellite Instable Tumors and is under evaluation in Lynch syndrome carriers <i>Elisa Scarselli (Italy)</i></p>
13:30-14:30	Lunch
14:30-16:30	<p>Joint ESCP-EHTG Hereditary Surgery Symposium See page 24-25 for details</p>
14:30-16:30	Parallel Working Groups 7-9
14:30-16:30	<p>Group 7 – Genetics Counselling & Management (incl. Lab diagnosis, NA seq, MMR variant interpretation)</p> <p>Section 1: Lynch Syndrome - national strategies and registries <i>Chair: Fiona Laloo (UK)</i></p> <p>The UK-model <i>Laura Monje-Garcia, UK</i></p> <p>The DK-model <i>Christina Therkildsen, Denmark</i></p> <p>Section 2: Ethical dilemmas – Risk information in families <i>Chair: Kaisa Fritzell (Sweden)</i></p> <p>Experiences from direct provider-mediated cascade-testing in Lynch syndrome families – the Danish model <i>Lars Lindberg (Denmark)</i></p> <p>Mismatch repair deficiency – extent of investigation and management of “unexplained” cases: UK cancer genetics group national consensus meeting <i>Terri McVeigh (UK)</i></p>

Scientific Program

Day 2 – Saturday, September 30th

8'	<p>Lynch Syndrome Super-spreader: Legal, ethical, regulatory and social implications of sperm donors' genetic screening <i>Zohar Levi (Israel)</i></p> <p>Section 3: Diagnostic tools – dilemmas <i>Chair: Inge Bernstein (Denmark)</i></p> <p>MLH1 promotor hypermethylation in colorectal and endometrial carcinomas from patients with Lynch syndrome <i>Maartje Nielsen (Netherlands)</i></p> <p>An Exploration of the Somatic and Germline Mutational Profiles of Early-Onset Colorectal Cancer Based on Two UK Patient Cohorts <i>Penelope Edwards (UK)</i></p> <p>Challenging interpretation of germline TP53 variants <i>Henriett Butz (Hungary)</i></p> <p>Section 4: Posters – Two minutes appetizer + 1 slide <i>Chair: Inge Bernstein (Denmark)</i></p> <p>Prevalence of CHEK2-Pathogenic/Likely Pathogenic Variant - Positive and Management in Hereditary Breast Cancer Syndrome in Our Centre. <i>Francisco Javier Jiménez-Ruiz (Spain)</i></p> <p>Development and performance of a PMS2-specific NGS product for genetic testing of Lynch Syndrome <i>Jessica De Loma Olson (Sweden)</i></p> <p>Enhancing interpretation and classification of POLE and POLD1 variants: Gene-specific recommendations and in vitro functional study system development <i>Julen Viana (Spain)</i></p> <p>RNA-based analyses expand the molecular genetic diagnostic workflow of Lynch syndrome <i>Vince Kornél Grolmusz (Hungary)</i></p>
----	---

Scientific Program

Day 2 – Saturday, September 30th

2' **The landscape of Lynch syndrome in the Israeli population**
Zohar Levi (Israel)

Summery and Discussion
Fiona Lalloo (UK)

14:30-16:30 **Group 8 – Gynecology, urology and other extra-intestinal cancers**
Chairs: Emma Crosbie (UK)
Maria Rasmussen (Denmark)
John Burn (UK)

8' + 2' **Mismatch repair deficiency testing in Lynch syndrome-associated urothelial tumors**
Maria Rasmussen (Denmark)

ONLY AS VIRTUAL POSTER
8' + 2' **Lynch Syndrome: Does Hormonal Contraception Protect Against Endometrial Cancer?**
Marie Mawet (France)

8' + 2' **Highly sensitive microsatellite instability assessment in minimally invasive gynaecological samples allows detection of mismatch repair-deficient endometrial cancer**
Julia Canet (Spain)

8' + 2' **A pilot study using the Newcastle MSI-Plus assay as a “urine liquid biopsy” in patients with upper tract urothelial cancers and in asymptomatic MSH2 Lynch syndrome carriers.**
Rebecca Hall (UK)

8' + 2' **Outcomes of Lynch syndrome endometrial cancer surveillance in a nation-wide cohort**
Anja Wagner (Netherlands)

8' + 2' **MSI detection of MMR deficient endometrial tumours is influenced by assay sensitivity and MMR gene affected**
Michael Jackson (UK)

8' + 2' **Breast magnetic resonance screening for BRCA and non-BRCA pathogenic variant carriers**
Mev Dominguez Valentin (Norway)

Scientific Program

Day 2 – Saturday, September 30th

8' + 2' **Home-based urine sampling for endometrial cancer detection in Lynch syndrome**
Jean-Ellen Johnson (UK)

8' + 2' **A Mismatch in Guidelines for Lynch Syndrome: A Systematic Review & Meta-Analysis**
Neil Ryan (UK)

14:30-16:30 **Group 9 – Immunology and Pathology**
Chairs: Shizuko Sei (USA)
Vinaya Gunasri (UK)
Aysel Ahadova (Germany)

30' **CAPIT Center for LNP RNA Cancer Immunoprevention**
Steve Lipkin (USA)

30' **Relationship between neoantigen load and the T cell response in mismatch-repair deficient / ultramutated POLE-mutant cancers**
David Church (UK)

9' **The immune profile of Lynch syndrome-associated colorectal adenomas pinpoints the main determinants of immune activation**
Lena Bohaumilitzky (Germany)

9' **Immune evasion is more frequent among prevalent than incident Lynch syndrome colorectal cancers**
Aysel Ahadova (Germany)

9' **HLA Type as a possible modulator of cancer risk in Lynch syndrome: first data from the INDICATE Network**
Aysel Ahadova (Germany)

9' **Math4INDICATE - Methodological challenges for investigating the influence of the HLA genotype on cancer risk in Lynch syndrome**
Saskia Haupt (Germany)

9' **Tumor3D – A platform for virtual 3D tumor models from histology sections**
Alexander Zeilmann (Germany)

15' **Discussion**

Scientific Program

Day 2 – Saturday, September 30th

16:30-17:00 Coffee Break

17:00-18:45

CMMRD Session

*Chairs: Crystelle Colas (France)
Katharina Wimmer (Austria)*

CMMRD: the clinical spectrum and differential diagnoses

15' *Katharina Wimmer (Austria)*

New guidelines for CMMRD diagnosis, counseling, surveillance, clinical management and quality of life

15' *Crystelle Colas (France)*

Gastroenterological surveillance for CMMRD

15' *Mariëtte van Kouwen (Netherlands)*

Place of immune checkpoint therapy in CMMRD

15' *Léa Guerrini-Rousseau (France)*

Neuroimaging features of CMMRD syndrome and comparison of brain MRIs of children with high-grade gliomas according to MMR gene mutational status

15' *Volodia Dangouloff-Ros (France)*

Update about systemic immunological implications of CMMRD

15' *Matthias Kloor (Germany)*

18:30-18:45 CMMRD Speed Talks

A validated highly sensitive microsatellite instability assay accurately identifies biallelic germline PMS2 mutation carriers among Constitutional Mismatch Repair Deficiency individuals.

5' *Marta Pineda (Spain)*

Cases of constitutional mismatch repair deficiency mimicking Lynch syndrome caused by hypomorphic variants

5' *Richard Gallon (UK)*

Scientific Program

Day 2 – Saturday, September 30th

Digestive burden of patients with Constitutional Mismatch Repair Deficiency syndrome, diagnostic pitfalls and experience of immunotherapy: a report from the C4CMMRD database.

5' *Crystelle Colas (France)*

19:30 +

Conference Dinner





EHTG-ESCP international Surgery Day “iSTOIC”*

Day 2 – Saturday, September 30th

09:00-11:00	IPAA Technical Considerations I <i>Chairs: Valerio Celentano (UK)</i> <i>Dieter Hahnloser (Switzerland)</i>
09:00-09:20	Staging, timing and technical details of IPAA in FAP <i>Feza Remzi (USA)</i>
09:20-9:40	What is different for UC-Pouches and FAP-pouches? <i>Janindra Warsusavitarné (UK)</i>
09:40-10:00	Plenary Discussion
10:00-10:20	Stoma yes or no for FAP pouches – virtual ileostomy, early stoma closure? <i>Gianlucca Pellino (Italy)</i>
10:20-10:40	Appraisal of robotic IPAA – equal or better? <i>Marcos Gomez Ruiz (Spain)</i>
10:40-11:00	Plenary Discussion
11:00-11:30	Coffee Break
11:30-13:30	Surgery and Genetics <i>Chairs: John Burn (UK)</i> <i>Neil Smart (UK)</i>
11:30-11:50	Crash Course for Surgeons: What you always wanted to know and never dared to ask about hereditary cancer <i>Heather Hampel (USA)</i>
11:50-12:10	Collaborative Networks & advancing genomics knowledge for Surgeons <i>Frank McDermott (UK)</i>
12:10-12:30	Implementing a nurse led mainstreaming pathway for Lynch Syndrome <i>Emma Jenkins (UK)</i>

* International Surgical Group of Those Operating on Inherited colorectal Cancer

EHTG-ESCP international Surgery Day “iSTOIC”*

Day 2 – Saturday, September 30th

12:30-13:30	Plenary discussion
13:30-14:30	Lunch Break
14:30-16:30	IPAA Technical Considerations II <i>Chairs: Narimantas Samalavičius (Lithuania)</i> <i>Feza Remzi (USA)</i>
14:30-14:50	Is there still a place for hand-assisted IPAA? Worth learning? <i>Narimantas Samalavičius (Lithuania)</i>
14:50-15:10	Pouch failure: taTME redo pouch <i>Antonio Lacy (Spain)</i>
15:10-15:30	Pouch failure: is continent ileostomy an alternative? <i>Gabriela Mölslein (Germany)</i>
15:30-15:45	FAP and Desmoids <i>Matt Kalady (USA)</i>
15:45-16:00	FAP and Endometriosis – is it an issue? <i>Hermann Kessler (USA)</i>
16:00-16:30	Plenary Discussion



**European Hereditary
Tumour Group**

Scientific Program

Day 3 – Sunday, October 1st

08:00-09:00 EHTG Business Meeting

09:00-10:00 **WG Reporting Back Session and Collaborative Studies**

*Chairs: Laura Valle (Spain)
Rolf Sijmons (Netherlands)
TBD*

10:00-10:30 **Coffee Break**

10:30-11:30 **Hot Topic / Late Breaking Abstracts**

*Chairs: Lone Sunde (Denmark)
Alessandro Manucci (Italy)
Lior Katz (Israel)*

10:30-10:45 **Colonoscopy interval in LS: Time to start a clinical trial?**

Martina Cavestro (Italy)

10:45-11:00 **FIT for surveillance in LS**

Kevin Monahan (UK)

11:00-11:15 **Comprehensive Analysis of Germine Drivers in Endometrial Cancer**

Ying Liu (USA)

10:30-11:30 **Late Abstract 1**

11:30-12:30 **Session – Pathology and clinical data in childhood in FAP, MAP, JPS, PHTS**

*Chairs: Katharina Wimmer (Austria)
Marion Dhooge (France)
TBD*

*Speakers: Andrew Latchford (UK)
NN*

Scientific Program

Day 3 – Sunday, October 1st

12:30-13:30

Lunch: Networking with patients and their organisations

- Patient presentations about their live experiences
- Priorities for research topics
- Gaps in clinical care and patient resources
- Psychosocial aspect for hereditary cancer patients

*Chairs: Kelly Kohut (UK)
Simone Widhalm (Germany)
Nicole Reents (Germany)*

13:30-14:15

Newly emerging technologies

*Chairs: Zsofia Stadler (USA)
Ellis Eikenboom (Netherlands)
NN*

13:30-13:45

Liquid biopsy in CRC for early detection and therapy monitoring based on whole genome sequencing data

Ariane Hallermayr (Germany)

13:45-14:00

MMR functional analysis in diagnostics: the INVUSE project

Tjakko J. van Ham (Netherlands)

14:00-14:15

Implementing RAMAN spectroscopy in screening for Lynch patients

Dean Harris (UK)

14:15-14:30

Farewell

Faculty

Ahadova, Aysel	University Hospital Heidelberg Heidelberg, Germany
Al Maliki, Husam	Sussex Medical School Brighton, United Kingdom
Andini, Katarina	UMCG - University Medical Centre Groningen Groningen, Netherlands
Arber, Nadir	Sourasky Medical Center Tel-Aviv, Israel
Backman, Ann-Sofie	Karolinska University Hospital Stockholm, Sweden
Bajwa-ten Broeke, Sanne	UMCG - University Medical Centre Groningen Groningen, Netherlands
Bauerfeind, Peter	Hirslanden Clinic St. Anna Zürich, Switzerland
Bernstein, Inge	Aalborg University Hospital Aalborg, Denmark
Bisseling, Tanya	Radboud University Medical Center Nijmegen, Netherlands
Bohaumilitzky, Lena	University Hospital Heidelberg Heidelberg, Germany
Buchanan, Dan	University of Melbourne Melbourne, Australia
Burn, John	Newcastle University Newcastle upon Tyne, United Kingdom
Butz, Henriett	Semmelweis University Budapest, Hungary
Canet-Hermida, Julia	Catalan Institute of Oncology (IDIBELL) Hospitalet de Llobregat, Spain
Capella, Gabriel	Catalan Institute of Oncology (IDIBELL) Hospitalet de Llobregat, Spain
Cavestro, Martina	IRCCS San Raffaele Scientific Institute Milan, Italy

Faculty

Celentano, Valerio	Chelsea and Westminster Hospital NHS Foundation Trust London, United Kingdom
Chen-Shtoyerman, Rakefet	Ariel University Ariel, Israel
Church, David	University of Oxford Oxford, United Kingdom
Colas, Crystelle	Institut Curie Paris, France
Crosbie, Emma	Manchester University NHS Foundation Trust Manchester, United Kingdom
Dangouloff-Ros, Volodia	Necker University Hospital Paris, France
Darbyshire, Mandy	Manchester University NHS Foundation Trust Manchester, United Kingdom
De Loma Olson, Jessica	Devyser AB Hägersten, Sweden
de Voer, Richarda	Radboud University Medical Center Nijmegen, Netherlands
Dhooge, Marion	Hopital Cochin Paris, France
Diez de los Tios, Celia	University of Navarra Madrid, Spain
Dominguez Valentin, Mev	Oslo University Hospital Oslo, Norway
Edwards, Penelope	St. Marks Hospital London, United Kingdom
Eikenboom, Ellis	Erasmus MC Cancer Institute Rotterdam, Netherlands
Erkan, Pekcan	Tampere University and TAYS Cancer Centre Tampere, Finland
Frank, Alexander	Karolinska University Hospital Stockholm, Sweden
Fritzell, Kaisa	Karolinska University Hospital Stockholm, Sweden

Faculty

Fruscio, Robert	Università degli Studi di Milano-Bicocca Milan, Italy
Gallon, Richard	Newcastle University Newcastle upon Tyne United Kingdom
Georgiou, Demetra	Imperial and North West London Healthcare London, United Kingdom
Goldberg, Yael	Rabin Medical Center Petach Tikva, Israel
Gomez Ruiz, Marcos	Hospital Universitario Marques de Valdecilla Santander, Spain
Grolmusz, Vince Kornél	National Institute of Oncology Budapest, Hungary
Guerrini-Rousseau, Léa	Université Paris-Saclay Villejuif, France
Gunasri, Vinaya	University College London London, United Kingdom
Hahnloser, Dieter	Centre Hospitalier Universitaire Vaudois Lausanne, Switzerland
Half, Elisabeth	Rambam Health Care Campus Haifa, Israel
Hall, Rebecca	Newcastle University Newcastle upon Tyne United Kingdom
Hallermayr, Ariane	MGZ Medical Center of Genetics Munich, Germany
Hampel, Heather	Ohio State University Columbus OH, USA
Haraldsdottir, Sigurdís	Landspítali University Hospital Reykjavík, Iceland
Harris, Dean	Swansea University Swansea, United Kingdom
Hasnis, Erez	Rambam Health Care Campus Haifa, Israel
Haupt, Saskia	University Hospital Heidelberg Heidelberg, Germany

Faculty

Helderman, Noah Cornelis	LUMC Leiden University Medical Center Leiden, Netherlands
Hodan, Rachel	Stanford University Palo Alto, USA
Hokkanen, Kalle	Tampere University and TAYS Cancer Centre Tampere, Finland
Jackson, Michael	Newcastle University Newcastle upon Tyne United Kingdom
Jelsig, Anne Marie	Rigshospitalet Copenhagen, Denmark
Jenkins, Emma	South Devon Healthcare NHS Foundation Trust Torquai, United Kingdom
Jiménez-Ruiz, Francisco Javier	Hospital Universitario Juan Ramón Jiménez Huelva, Spain
Johnson, Jean-Ellen	Manchester University NHS Foundation Trust Manchester, United Kingdom
Jokela, Tiina	University of Jyväskylä Jyväskylä, Finland
Kalady, Matt	Ohio State University Columbus OH, USA
Katz, Lior	Hadassah Medical Center Jerusalem, Israel
Kessler, Hermann	Cleveland Clinic Cleveland, Ohio, USA
Kloor, Matthias	University Hospital Heidelberg Heidelberg, Germany
Kohut, Kelly	St George's University Hospitals NHS Foundation Trust London, United Kingdom
Kozziel, Anna	London North West University Healthcare NHS Trust London, United Kingdom
Lacy, Antonio	Clinica Rotger Barcelona, Spain

Faculty

Laloo, Fiona	Manchester Centre for Genomic Medicine Manchester, United Kingdom
Latchford, Andrew R.	St. Marks Hospital London, United Kingdom
Levi, Zohar	Rabin Medical Center Petach Tikva, Israel
Lindberg, Lars	Copenhagen University Hospital Hvidovre, Denmark
Lipkin, Steve	Weill Cornell Medicine New York, USA
Liu, Ying	Memorial Sloan Kettering Cancer Center New York, USA
Loughrey, Mechelle	St. Vincent's University Hospital Dublin, Ireland
Lubinski, Jan	Pomeranian Medical University Szczecin, Poland
Mäki-Nevala, Satu	University of Helsinki Helsinki, Finland
Manucci, Alessandro	San Raffaele Hospital Milan, Italy
Mawet, Marie	Hopital Tenon Paris, France
McDermott, Frank	Royal Devon University Healthcare Trust Exeter, Ireland
McVeigh, Terri	Royal Marsden NHS Foundation Trust London, United Kingdom
Moeslein, Gabriela	Evangelic Bethesda Hospital Duisburg, Germany
Møller, Pål	The Norwegian Radium Hospital Oslo, Norway
Monahan, Kevin	St. Marks Hospital London, United Kingdom
Monje-Garcia, Laura	London North West University Healthcare NHS Trust London, United Kingdom

Faculty

Moschini, Marco	San Raffaele Hospital Milan, Italy
Nielsen, Maartje	LUMC Leiden University Medical Centre Leiden, Netherlands
Nordstroem, Ulla	Rigshospitalet Copenhagen, Denmark
Padrik, Peeter	Tartu University Hospital Tartu, Estonia
Pellino, Gianluca	Università degli Studi dalla Campania „Luigi Vanvitelli“ Naples, Italy
Pineda, Marta	Catalan Institute of Oncology (IDIBELL) Hospitalet de Llobregat, Spain
Puzzono, Marta	University of Siena Siena, Italy
Rafnsdóttir, Ásthildur	Landspítali University Hospital Reykjavik, Iceland
Rasmussen, Maria	Copenhagen University Hospital Hvidovre, Denmark
Reents, Nicole	SemiColon Germany Mönchengladbach, Germany
Remzi, Feza	NYU Langone Inflammatory Bowel Disease Center New York, USA
Ryan, Neil	University of Edinburgh Edinburgh, United Kingdom
Samalavicius, Narimantas	Klaipeda University Hospital Klaipeda, Lithuania
Sanctorum Belgium	Katlijn FAPA Brussels
Sanderson, Amy	Sheffield Teaching Hospitals Sheffield, United Kingdom
Sayyed, Raza	Patel Hospital Karachi, Pakistan
Scarselli, Elisa	Nouscom Srl Rome, Italy



Faculty

Sei, Shizuko	UCL Cancer Institute London, USA
Shiu, Kai-Keen	UCL Cancer Institute London, United Kingdom
Sievänen, Tero	University of Jyväskylä Jyväskylä, Finland
Sijmons, Rolf	University Medical Centre Groningen Groningen, Netherlands
Sinicrope, Frank A.	Mayo Clinic Rochester, USA
Smart, Neil	Royal Devon & Exeter Hospital Exeter, United Kingdom
Stadler, Zsofia	Memorial Sloan Kettering Cancer Center New York, USA
Sunde, Lone	Aalborg University Hospital Aalborg, Denmark
Swinyard, Otilie	Barts Cancer Institute London, United Kingdom
Terlouw, Diantha	LUMC Leiden University Medical Centre Leiden, Netherlands
Terradas, Mariona	Catalan Institute of Oncology (IDIBELL) Hospitalet de Llobregat, Spain
Therkildsen, Christina	Copenhagen University Hospital Hvidovre, Denmark
Thomas, Laura	Swansea University Swansea, United Kingdom
Valle, Laura	Catalan Institute of Oncology (IDIBELL) Hospitalet de Llobregat, Spain
van der Ham, Tjakko	Erasmus MC Cancer Institute Rotterdam, Netherlands
van Enckevort, Esther	UMCG Houten, Netherlands
van Kouwen, Mariëtte	Radboud University Medical Center Nijmegen, Netherlands

Faculty

Varde, Avani	Imperial College London London, United Kingdom
Viana-Errasti, Julen	Catalan Institute of Oncology (IDIBELL) Hospitalet de Llobregat, Spain
Wagner, Anja	Erasmus MC Cancer Institute Rotterdam, Netherlands
Walton Bernstedt, Sophie	Karolinska University Hospital Stockholm, Sweden
Warsusavitarné, Janindra	St. Marks Hospital London, United Kingdom
Widhalm, Simone	Semi-Colon Düsseldorf, Germany
Wimmer, Katharina	Medical University of Innsbruck Innsbruck, Austria
Young, Julie	Patient representative Southampton, United Kingdom
Zaffaroni, Gloria	Evangelic Bethesda Hospital Duisburg, Germany/Italy
Zeilmann, Alexander	University Hospital Heidelberg Heidelberg, Germany





7TH ANNUAL MEETING
Vilnius • 2023



Scan the QR code
to sign up today

www.ehtg.org